OASMY (Vivesto AB) Change In Receivables : $-0.06 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Change In Receivables?

Vivesto AB's change in receivables for the quarter that ended in Sep. 2024 was $0.10 Mil. It means Vivesto AB's Accounts Receivable declined by $0.10 Mil from Jun. 2024 to Sep. 2024 .

Vivesto AB's change in receivables for the fiscal year that ended in Dec. 2023 was $0.53 Mil. It means Vivesto AB's Accounts Receivable declined by $0.53 Mil from Dec. 2022 to Dec. 2023 .

Vivesto AB's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vivesto AB's liquidation value for the three months ended in Sep. 2024 was $2.47 Mil.

Vivesto AB Change In Receivables Historical Data

The historical data trend for Vivesto AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Change In Receivables Chart

Vivesto AB Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.84

-1.29

5.37

2.02

0.53

Vivesto AB Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															0.12	0.17	-0.31	-0.02	0.10

Vivesto AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Vivesto AB (OTCPK:OASMY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vivesto AB's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Vivesto AB's accounts receivable are only considered to be worth 75% of book value:

Vivesto AB's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.997	-	1.529	+	0.75 * 0	+	0.5 * 0
=	2.47

Vivesto AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivesto AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VIVE:Sweden OMAX:Germany

Address

Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website

https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.